Neuromarket
Neuromarket ‘Street drugs’, – desire and despair – have a new market.
Tag: Ketamine
BAP Summer Meeting 2024: Guest Lecture
This Wednesday, Professor John Krystal, Yale University, has been invited by BAP to give this talk: ‘Linking depression pathophysiology to the mechanism of action of ketamine and “next generation” treatments’ … Continue reading BAP Summer Meeting 2024: Guest Lecture
‘Preliminary’
Confirmed symposia for next year’s Summer Meeting of the British Association for Psychopharmacology [BAP] indicate an increasing defensiveness: BAP ‘symposia’ are generally sponsored by the pharmaceutical industry. BAP meetings continue … Continue reading ‘Preliminary’
Neuromarket
Neuromarket ‘Street drugs’, – desire and despair – have a new market.
Esketamine: Regulators and a confusing narrative
I recently shared a BMJ report that outlined the approval of Esketamine in Europe: Since sharing this news, the following rapid response by the MHRA [The Medicines and Healthcare products … Continue reading Esketamine: Regulators and a confusing narrative
Ketamine: “lost in translation?”
Last month I shared a BMJ Editorial on Ketamine by Dr Sameer Jauhar and Dr Paul Morrison. Since then there have been a number of published BMJ responses and replies. … Continue reading Ketamine: “lost in translation?”
“We should cautiously welcome this new therapeutic option”
There has long been awareness of the effects of Ketamine use among those who have taken it unprescribed. Given the lack of long term data on this specific “new therapeutic … Continue reading “We should cautiously welcome this new therapeutic option”
Surgeon’s Hall: ‘Improving our understanding and treatment of depression’
As a Member of the Royal College of Psychiatrists I have received an invitation to the Autumn Meeting of the Royal College of Psychiatrists in Scotland. This is to be … Continue reading Surgeon’s Hall: ‘Improving our understanding and treatment of depression’